211 related articles for article (PubMed ID: 30450575)
1. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008.
Højfeldt SG; Wolthers BO; Tulstrup M; Abrahamsson J; Gupta R; Harila-Saari A; Heyman M; Henriksen LT; Jónsson ÒG; Lähteenmäki PM; Lund B; Pruunsild K; Vaitkeviciene G; Schmiegelow K; Albertsen BK;
Br J Haematol; 2019 Feb; 184(3):405-417. PubMed ID: 30450575
[TBL] [Abstract][Full Text] [Related]
2. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
[TBL] [Abstract][Full Text] [Related]
3. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
[TBL] [Abstract][Full Text] [Related]
4. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
[TBL] [Abstract][Full Text] [Related]
5. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
[TBL] [Abstract][Full Text] [Related]
6. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
[TBL] [Abstract][Full Text] [Related]
7. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
[TBL] [Abstract][Full Text] [Related]
8. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
9. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
10.
Liu S; Gao C; Wu Y; Lin W; Li J; Xue T; Wang L; Zheng H; Zhang R
Pharmacogenomics; 2021 Nov; 22(17):1135-1142. PubMed ID: 34747637
[No Abstract] [Full Text] [Related]
11. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
[TBL] [Abstract][Full Text] [Related]
12. HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia.
Kutszegi N; Yang X; Gézsi A; Schermann G; Erdélyi DJ; Semsei ÁF; Gábor KM; Sági JC; Kovács GT; Falus A; Zhang H; Szalai C
Haematologica; 2017 Sep; 102(9):1578-1586. PubMed ID: 28596278
[TBL] [Abstract][Full Text] [Related]
13. Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Gottschalk Højfeldt S; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Marquart HV; Vaitkeviciene G; Lepik K; Heyman M; Schmiegelow K; Albertsen BK
Blood; 2021 Apr; 137(17):2373-2382. PubMed ID: 33150360
[TBL] [Abstract][Full Text] [Related]
14. [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].
Sikorska-Fic B; Makowska K; Rokicka-Milewska R
Wiad Lek; 1998; 51 Suppl 4():233-6. PubMed ID: 10731974
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
Browne EK; Moore C; Sykes A; Lu Z; Jeha S; Mandrell BN
J Pediatr Oncol Nurs; 2018; 35(2):103-109. PubMed ID: 29161979
[TBL] [Abstract][Full Text] [Related]
16. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.
Fernandez CA; Smith C; Yang W; Mullighan CG; Qu C; Larsen E; Bowman WP; Liu C; Ramsey LB; Chang T; Karol SE; Loh ML; Raetz EA; Winick NJ; Hunger SP; Carroll WL; Jeha S; Pui CH; Evans WE; Devidas M; Relling MV
Blood; 2015 Jul; 126(1):69-75. PubMed ID: 25987655
[TBL] [Abstract][Full Text] [Related]
18. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
Vieira Pinheiro JP; Müller HJ; Schwabe D; Gunkel M; Casimiro da Palma J; Henze G; von Schütz V; Winkelhorst M; Würthwein G; Boos J
Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290
[TBL] [Abstract][Full Text] [Related]
19. Trypsin-encoding
Wolthers BO; Frandsen TL; Patel CJ; Abaji R; Attarbaschi A; Barzilai S; Colombini A; Escherich G; Grosjean M; Krajinovic M; Larsen E; Liang DC; Möricke A; Rasmussen KK; Samarasinghe S; Silverman LB; van der Sluis IM; Stanulla M; Tulstrup M; Yadav R; Yang W; Zapotocka E; Gupta R; Schmiegelow K;
Haematologica; 2019 Mar; 104(3):556-563. PubMed ID: 30467200
[TBL] [Abstract][Full Text] [Related]
20. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Vieira Pinheiro JP; Lanversa C; Würthwein G; Beier R; Casimiro da Palma J; von Stackelberg A; Boos J
Leuk Lymphoma; 2002 Oct; 43(10):1911-20. PubMed ID: 12481884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]